JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment

Not intended for UK and US audiences JASCAYD® (nerandomilast) now approved by Japan’s MHLW for the treatment of adults with idiopathic pulmonary fibrosis and adults with progressive pulmonary fibrosis Approval enables access to the first oral PDE4B inhibitor with antifibrotic and immunomodulatory effects authorized for use in IPF and PPF, and the first new treatment in... The post JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment appeared first on Montreal Gazette .

Original source: Montreal Gazette